Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marshall David Crew is active.

Publication


Featured researches published by Marshall David Crew.


Molecular Pharmaceutics | 2008

Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview

Dwayne Thomas Friesen; Ravi Mysore Shanker; Marshall David Crew; Daniel Tod Smithey; William John Curatolo; James Alan Schriver Nightingale

Spray-dried dispersions (SDDs) of low-solubility drugs have been prepared using the polymer hydroxypropyl methylcellulose acetate succinate (HPMCAS). For a variety of drug structures, these SDDs provide supersaturation in in vitro dissolution determinations and large bioavailability increases in vivo. In bile-salt/lecithin in vitro solutions, these SDDs provide amorphous drug/polymer colloids and an increased concentration of free drug and drug in micelles relative to crystalline or amorphous drug. As dry powders, the SDDs are a single amorphous phase in which the drug remains amorphous and dispersed and does not crystallize over storage times relevant for practical drug products. A melting temperature (Tm)/glass-transition temperature (Tg) (K/K) versus log P map for 139 compounds formulated as SDDs provides a perspective on an appropriate formulation strategy for low-solubility drugs with various physical properties.


Mini-reviews in Medicinal Chemistry | 2006

Glycogen phosphorylase inhibitor

Marshall David Crew; Dwayne Thomas Friesen; Bruno C. Hancock; Chris Macri; James Alan Schriver Nightingale; Ravi Mysore Shanker

Type 2 diabetes is a complex metabolic disease with hyperglycemia as its recognizable hallmark. Hepatic glucose output is elevated in Type 2 diabetic patients, and evidence suggests drugs which lower hepatic glucose production are effective antihyperglycemic agents. Glycogenolysis, which is the release of monomeric glucose from its polymeric storage form called glycogen, is a key contributor to hepatic glucose output. Glycogen phosphorylase is the enzyme that catalyzes this process. This review covers advances in the design of small molecule inhibitors of this enzyme, their biological activity, and their potential as effective antihyperglycemic agents for the treatment of Type 2 diabetes.


Optics Letters | 1998

Long holographic lifetimes in bacteriorhodopsin films

John D. Downie; Doǧan A. Timuçin; Daniel Tod Smithey; Marshall David Crew

The D85N genetic variant of bacteriorhodopsin (BR) displays a nearly permanent lifetime of the photochromic P(490) state. We present pump-probe measurements that demonstrate this behavior. However, diffraction efficiency measurements made from holograms recorded in a hydrated D85N film show markedly different decay behavior, suggesting that a molecular diffusion process is occurring in the film. Holograms recorded with different grating frequencies display correspondingly different decay times, thus supporting this hypothesis. A thin D85N film was fabricated that was chemically cross linked, resulting in the elimination of diffusion of BR molecules within the polymer matrix. This film exhibits a grating lifetime of the order of weeks or more, thus permitting the long-term holographic storage of information.


SPIE's International Symposium on Optical Science, Engineering, and Instrumentation | 1998

Bit-error-rate issues for holographic data storage in bacteriorhodopsin films

John D. Downie; Dogan A. Timucin; Charles K. Gary; Meric Oezcan; Daniel Tod Smithey; Marshall David Crew

Photochromic films made from bacteriorhodopsin (BR) possess many desirable characteristics for a candidate holographic optical data storage medium. These properties include optical erasability, high spatial resolution, adequate diffraction efficiency, flexible film formats, durability, an optimal recording/readout wavelength of about 680 - 690 nm, and potentially inexpensive cost. In this paper, we experimentally study the raw bit-error-rate (BER) achievable with BR films made from the genetic variant known as D85N. Experimental data is collected for digital bit patterns fabricated as chrome-on- glass masks, at two different spatial resolutions. The results show that films fabricated from D85N have good potential for use in holographic data storage systems, but that further effort must be devoted to the film fabrication process in order to minimize optical nonuniformity and scattering losses.


Archive | 2003

Immediate release dosage forms containing solid drug dispersions

Leah Elizabeth Appel; John E. Byers; Marshall David Crew; Dwayne Thomas Friesen; Bruno C. Hancock; Stephen J. Schadtle


Archive | 2002

Pharmaceutical compositions containing polymer and drug assemblies

Walter Christian Babcock; Marshall David Crew; Dwayne Thomas Friesen; Mark David Rabenstein; Ravi Mysore Shanker; Daniel Tod Smithey


Archive | 2004

Azithromycin dosage forms with reduced side effects

Timothy Arthur Hagen; Julian B. Lo; Avinash Govind Thombre; Scott Max Herbig; Leah Elizabeth Appel; Marshall David Crew; Dwayne Thomas Friesen; David Keith Lyon; Scott B. Mccray; James Blair West


Archive | 2006

Pharmaceutical compositions of drugs and neutralized acidic polymers

Marshall David Crew; Dwayne Thomas Friesen; Rodney James Ketner; Ravi Mysore Shanker; James Blair West


Archive | 2008

Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer

Corey Jay Bloom; Marshall David Crew; Daniel Tod Smithey; Warren Kenyon Miller; Michael Mark Morgen


Archive | 2004

Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers

Marshall David Crew; Dwayne Thomas Friesen; Warren Kenyon Miller; Ravi Mysore Shanker; Daniel Tod Smithey

Collaboration


Dive into the Marshall David Crew's collaboration.

Researchain Logo
Decentralizing Knowledge